<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04275583</url>
  </required_header>
  <id_info>
    <org_study_id>TQB3602-I-01</org_study_id>
    <nct_id>NCT04275583</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule</brief_title>
  <official_title>A Phase I, Open-label, Dose Escalation and Expansion Study to Evaluate the Tolerance and Pharmacokinetics of TQB3602 Capsule</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the tolerance, dose-limiting toxicity (DLT), phase II recommended
      dose (RP2D), and maximum tolerated dose (MTD) of single and multiple oral doses of TQB3474 in
      patients with advanced malignant tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT)</measure>
    <time_frame>Baseline up to 28 days</time_frame>
    <description>Subjects appear the following toxic reaction relate to the drug after treatment within 28 days ：III °or above of non-hematological toxicity, IV° hematological toxicity , III ° neutropenia associated with fever, III ° thrombocytopenia with bleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>0hour, 15minutes, 0.5hour, 1hour, 1.5hour, 2hour, 4hour, 8hour, 12hour, 24hour, 48hour, 96hour, 120hour, 144hour after oral administration of day 1 and day 15; Hour 0 of day 8 , hour 0 of day 29.</time_frame>
    <description>Cmax is the maximum plasma concentration of TQB3602 or metabolite(s).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>0hour, 15minutes, 0.5hour, 1hour, 1.5hour, 2hour, 4hour, 8hour, 12hour, 24hour, 48hour, 96hour, 120hour, 144hour after oral administration of day 1 and day 15; Hour 0 of day 8 , hour 0 of day 29.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3602 by assessment of time to reach maximum plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-t</measure>
    <time_frame>0hour, 15minutes, 0.5hour, 1hour, 1.5hour, 2hour, 4hour, 8hour, 12hour, 24hour, 48hour, 96hour, 120hour, 144hour after oral administration of day 1 and day 15; Hour 0 of day 8 , hour 0 of day 29.</time_frame>
    <description>To characterize the pharmacokinetics of TQB3602 by assessment of area under the plasma concentration time curve from zero to infinity.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>TQB3602 capsule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB3602 capsule administered orally on day 1, 8, 15 in 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB3602</intervention_name>
    <description>This is a kind of proteasome inhibitor.</description>
    <arm_group_label>TQB3602 capsule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Understood and signed an informed consent form. 2.18 and 75 years old , male or
             female. 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to
             2.

             4. Life expectancy ≥12 weeks. 5. Relapsed/refractory multiple myeloma had received at
             least two treatment methods.

             6. Male or female subjects should agree to use an adequate method of contraception
             starting with the first dose of study therapy through 6 months after the last dose of
             study (such as intrauterine devices , contraceptives or condoms) ；No pregnant or
             breastfeeding women, and a negative pregnancy test are received within 7 days before
             the randomization.

        Exclusion Criteria:

          -  1. Hypersensitivity to TQB3602 or its excipient. 2. Has peripheral nerve diseases ≥
             grade 2. 3. Has diarrhea grade &gt; 1 during screening period. 4. Has received
             chemotherapy, radiotherapy, targeted therapy, immunotherapy, or other systemic
             antitumor therapies within 14 days before the first dose.

             5. Has received ixazomib and less than 5 half-life before the first dose. 6. Has
             received allogeneic stem cell transplant. 7. Pregnant or lactating women. 8. Has
             participated in other clinical trials within 4 weeks before participating in this
             trial.

             9. According to the judgement of the researchers, there are other factors that
             subjects are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ting Niu, Doctor</last_name>
    <phone>028-85423046</phone>
    <email>tingniu@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China hospital, Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ting Niu, Doctor</last_name>
      <phone>028-85423046</phone>
      <email>tingniu@sina.com</email>
    </contact>
    <investigator>
      <last_name>Ting Niu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 16, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2020</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

